
Home \| About Us \| More Info \| Articles \| Archive \| Product List \| Store Map \| SEARCH \| Why Shop Crohns.net
100% Secure 1-877-240-7528 sales@crohns.net Help Basket

REFERENCES:

1. Brandtzaeg P. Current understanding of gastrointestinal immuno-regulation and its relation to food allergy. Ann NY Acad Sci. 2002;964:13-45.

2. Gershon MD. The Second Brain: A Groundbreaking New Understanding of Nervous Disorders of the Stomach and Intestine. Harper Collins, NY, 1998.

3. Sansonetti PJ. War and peace at the mucosal surface. Nat Rev Immunol. 2004;4:953-64.

4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31

5. McGarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastro-enterol. 2005;39:98-109.

6. Brandtzaeg P. Current understanding of gastrointestinal immuno-regulation and its relation to food allergy. Ann N Y Acad Sci. 2002;964:13-45.

7. Rook GAW, Adams G, Hunt J, et al. Mycobacteria and other environmental organisms as immuno-modulators for immuno-regulatory disorders. Springer Semin Immunol 2004.25:237-55.

8. Ashwood P, Anthony A, Pellicer AA, et al. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immuno-pathology. J Clin Immunol. 2003;23:504-17.

9. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005;81:341-54.

10. Guarner F, Magdelena JR. Gut flora in health and disease. Lancet. 2003;361:512-19.

11. Drossman DA, Camilleri M, Whitehead WE. American Gastro-enterological Association technical review on irritable bowel syndrome. Gastroenterology.1997;112:2137-2149.

12. Shanahan F. Host-Flora interactions in inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10(1): SI6-S24.

13. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 2000;45(Suppl 2):43-47.

14. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44·54.

15. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95:1231-38.

16. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr.2002;88(Suppl 1):S39-S49.

17. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia. and temporo-mandibular disorder. Arch Intern Med.2000;160:221-27.

18. Pimental M, Mayer AG, Park S, et al. Methane production during lactulose breath test is associated with gastro-intestinal disease presentation. Dig Dis Sci. 2003;48:86·92.

19. Pimentel M, Chow EJ, Hallegua D, et al. Small intestinal bacterial overgrowth: A possible association with fibromyalgia. J Musculoskelet Pain. 2001;9:107-13.

20. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852-58.

21. Schrezenemeir J, deVrese M. Prebiotics, probiotics, and symbiotics - approaching a definition. Am J Clin Nutr. 2001;73:361S-64S.

22. Isolauri E, SutasY, Kankaanpaa. et al. Probiotics: effects on immunity. Am J Clin Nutr. 2001;73:444S-50S.

23. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr.1995;125:1401-12.

24. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis.1999;3:197-202.

25. McGarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism and colon cancer: a review of the literature. J Clin Gastroenterol. 2005;39:98-109.

26. Teitelbaum JE, Walker WA. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu Rev Nutr. 2002;22:107-38.

27. Teitelbaum JE, Walker WA. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Ann Rev Nutr. 2002;22:107-38.

28. Spiller R. Probiotics: an ideal anti-inflammatory treatment for IBS Gastroenterology.2005;128:783-85.

29. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.Gastroenterology. 2005;128:541-51.

30. Sartori RB. Probiotic therapy for intestinal inflammation and infection. Curr Op Gastroenterol 2005;21:44-50.

31. Kalliomaki M, Salminen S, Avrilommi H, et al. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet. 2001;357:1076-79.

32. Kalliornaki M, Salminen S, Poussa T, et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361:1869-71.

33. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: a role in the treatment of intestinal infection and inflammation Gut. 2002;50(S3):III54-59.

34. Rosenfeldt V, Benfeldt E, Valerius NH. et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr. 2004;145:612-16.

35. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782-787.

36. Mahida YR. Epithelial cell responses. Best Pract Res Clin Gastro. 2004;18:241-53.

37. Pessi T, Sutas Y, Saxelin M, et al. Anti-proliferative effects of homogenates derived from five strains of candidate probiotic bacteria. Appl Environ Microbiol. 1999;65:475-78.

38. Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care. 2002;5:685-94.

39. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Investig. 2004;84:282-91.

40. DeMeo MT. Mutlu EA. Keshavarzian A, Tobin MC. Intestinal permeation and gastro-intestinal disease. J Clin Gastroenterol. 2002;34:385-96.

41. Baumgart DC. Dignass AU. Intestinal barrier function. Curr Op Clin Nutr Metab Care. 2002;5:685-694.

42. Wells CL, Hess DJ, Erlandsen SL. Impact of the indigenous flora in animal models of shock and sepsis. Shock. 2004;22:562-68.

43. Khanna A, Rossman JE, Fung HL, Caty MG. Intestinal and hemo-dynamic impairment following mesenteric ischemia/reperfusion. J Surg Res. 2001;99:114-19.

44. Fink MP. Intestinal epithelial hyper-permeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care.2003;9:143-51.

45. Bjarnason I, Peters TJ, Levi AJ. Intestinal permeability: clinical correlates. Dig Dis. 1986;4:83-92.

46. Wilson C, Rashid T, Tiwana H, et al. Cytotoxicity responses to peptide antigens in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2003;30:972-78.

47. Sahly H, Podschun R, Sass R, et al. Serum antibodies to Klebsiella capsular polysaccharides in ankylosing spondylitis. Arthritis Rheum. 1994;37:754-59.

48. Ebringer A. Khalalpour S, Wilson C. Rheumatoid arthritis and Proteus: a possible etiological association. Rheumatol Int. 1989;9:223-28.

49. Cookson W. The immuno-genetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol. 2004;4:978-88.

50. Hijazi Z, Molla AM, Muawad WMRA, et al. Intestinal permeability is increased in bronchial asthma. Arch Dis Child. 2004;89:227-29.

51. Israeli E, Berenshtein E, Wengrower D, et al. Glutamine enhances the capability of rat colon to resist inflammatory damage. Dig Dis Sci.2004;49:1705-12.

52. Salminen S, Bouley C, Boutron-Ruault MC, et al. Functional food science and gastro-intestinal physiology and function. Br J Nutr. 1998;80:S147-S71.

53. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol. 2004;4:407-19.

54. Fiocchi C. Inflammatory bowel disease: new insights into mechanisms of inflammation and increasingly customized approaches to diagnosis and therapy. Curr Opin Gastroenterol. 2004;20:309-10.

55. Lu L, Walker WA. Pathologic and physiologic interactions of bacteria with the gastro-intestinal epithelium. Am J Clin Nutr. 2001;73:1124S-30S.

56. Strober W, Kelsall B, Marth T. Oral tolerance. J Clin Immuno. 1998;18:1-30.

57. Shanahan F. Host-flora interactions in inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(1):SI6-S24.

58. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacterio-therapy. J Clin Gastroenterol. 2003;37:42-47.

59. Bradesi S, McRoberts JA, Anton PA, Mayer, EA. Inflammatory bowel disease and irritable bowel syndrome: separate or unified? Curr Opin Gastroenterol. 2003;9:336-42.

60. Rodriguez LAG, Ruigomez A, Wallander MA, et al. Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 2000;35:306-31.

61. Sutas Y, Hurme M, Isolauri E. Downregulation of anti CD3 antibody-induced IL-4 production by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes. Scand J Immunol. 1996;43:687-89.

62. C DeSimone. Personal communication. March 12, 2005.

63. Gionchietti P, Rizello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double blind placebo controlled trial. Gastroenterology. 2003;124:1202-9.

64. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.Gastroenterology. 2005;128:541-51.

65. Kalliomaki M, Salminen S, Poussa T, et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361:1869-71.

66. Sutas Y, Hurme M, Isolauri E. Downregulation of anti CD3 antibody-induced IL-4 production by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes. Scand J Immunol. 1996;43:687-89.

67. Tannock GW. The normal micro-flora: new concepts in health promotion. Microbial Sci.1988;5:4-8.

68. Guarner F. The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr Opin Gastroenterol. 2005;21:414-18.

69. Kleessen B, Kroesen AJ, Buhr HJ, Blauf M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol. 2002;37:1034-41.

70. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.Gastroenterol. 2000;119:305-309.

71. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-14.

72. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active alcerative colitis. Aliment Pharmacol Ther. 2004;20:1133-41.

73. Kruis W, Frec P, Pokrotneiks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-23.

74. Floch M. Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature. J Clin Gastro. 2005;39:S242-S46.

75. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143-47.

76. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38:S104-S106.

77. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of probiotic. VLS#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895-904.

78. Hatakka K. Savilahti E, Ponka A, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centers: double blind, randomised trial. Br Med J. 2001;322:1327-29.

79. Vanderhoof JA, Whitney DB, Antonson DL, et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999;135:564-68.

80. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002;109:678-84.

81. Hatakka K, Savilahti E, Ponka A, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centers: double blind, randomised trial. Br Med J. 2001;322:1327-29.

82. Cross HL. Immune-signaling by orally-delivered probiotic bacteria: effects on common mucosal immuno-responses and protection at distal mucosal sites. Int J Immunopathol Pharmacol. 2004;17:127-34.

83. Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr.2001;74:833-39.

84. Cummings JH, Antoine JM, Azpiroz F, et al. PASSCLAIM - Gut health and immunity. (1 Process for the Assessment of Scientific Support for Claims on Foods.) Eur J Nutr. 2004;43(S2):118-73.

85. Aguirre M, Collins MD. Lactic acid bacteria and human clinical infection. J Appl Bacteriol. 1993;75:95-107.

86. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38:62-69.

87. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Inf Dis.2002;35:1155-60.

88. Gibson GR. Dietary modulation of the human gut micro-flora using prebiotics. Br J Nutr.1998;80:S209-12.

89. Molis C, Flourie B, Ouarme F, et al. Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. Am J Clin Nutr. 1996;64:324-28.

PREVIOUS